Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type abstract
PMID
Authors Patrick Schöffski, Michael C. Heinrich, Jonathan C. Trent, Cesar Serrano, Sebastian Bauer, Margaret von Mehren, Neeta Somaiah, Peter Reichardt, George D. Demetri, Nick Lydon, Jaap Verweij, Vivek Kadambi, Jessica Christo, Sean Kim, Debbie Johnson, James Shao, Suzanne George
Title StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).
URL https://meetings.asco.org/abstracts-presentations/231575
Abstract Text Background: Resistance to kinase inhibitors in gastrointestinal stromal tumors (GIST) is mainly driven by secondary mutations in KIT, and currently available TKIs fail to inhibit the full spectrum of secondary KIT mutations.IDRX-42 is an oral, potent, and highly selective inhibitor of the KITtyrosine kinase, active against multiple primary and secondary resistance mutations in KIT-driven GIST. We present data from the ongoing FIH phase (ph) 1 study evaluating IDRX-42 in patients (pts) with metastatic GIST in 2nd or later lines of therapy after failure of imatinib and other drugs. Methods: This ph 1 study evaluates the safety, tolerability, pharmacokinetics, and antitumor activity of oral IDRX-42 in adult pts with KIT-mutant GIST in dose escalation (ph1a) and defines the recommended dose for continued development (ph 1b). Ph 1b comprises 4 cohorts including pts without prior exposure to TKIs (1st line), pts treated with prior imatinib only (2nd line) and later line treatment cohorts. Correlative studies include sequential circulating tumor DNA (ctDNA) analyses and metabolic imaging using 18FDG-PET. Results: As of January 2, 2024, 42 pts received IDRX-42 in the ph 1a portion of the study with median treatment duration of 19+ (range 2-73+) weeks, with 30 pts remaining on treatment as of data cutoff. The median number of prior TKI therapy lines was 4 (range 1-6). Primary driver mutations were in KIT exon (ex) 11 (n = 27), ex 9 (n = 13) and ex 8 (n = 2). To date, five dose levels (120, 240, 400 and 600 mg QD; 400 mg BID) have been deemed safe to continue escalation. MTD has not been reached. A total of 39/42 pts are evaluable for efficacy; 9 achieved objective partial response (PR) per mRECIST (5 confirmed, 4 pending) across all doses studied. Three of 6 patients receiving IDRX-42 as 2nd line therapy have confirmed PRs at 120 mg QD, 400 mg QD, and 400 mg BID respectively. The clinical benefit rate (mRECIST PR or stable disease ≥16 weeks) is 71% overall and 100% in 2nd line. Sequential analyses of ctDNA show reductions across all primary and secondary KITmutations. Treatment-related adverse events (TRAE, CTCAE v5.0) were mainly low grade. The most frequently reported TRAE (≥25%) were gastrointestinal symptoms (diarrhea, nausea, vomiting, decreased appetite, dysgeusia) and fatigue. Eight of 42 pts reported Grade 3/4 TRAEs including gastrointestinal symptoms, fatigue and anemia. Two events qualified as DLT, 1 at 600 mg QD (syncope) and 1 at 400 mg BID (vomiting); after dose reduction both pts continued IDRX-42 for more than 8 and 5 months, respectively. Only two patients discontinued treatment due to TRAEs. Conclusions: IDRX-42 demonstrates promising clinical activity and a favorable safety profile in patients with advanced GIST following resistance to prior TKIs. Dose finding continues, and additional cohorts are ongoing. Clinical trial information: NCT05489237.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KIT exon9 gastrointestinal stromal tumor predicted - sensitive IDRX-42 Phase I Actionable In a Phase I trial, IDRX-42 treatment demonstrated safety and resulted in 9 partial responses among 39 evaluable patients with gastrointestinal stromal tumors harboring a KIT exon 11 (n=27), exon 9 (n=13), or exon 8 (n=2) mutation with a clinical benefit rate of 71% overall and 100% as second-line treatment (J Clin Oncol 42, 2024 (suppl 16; abstr 11501); NCT05489237). detail...
KIT exon11 gastrointestinal stromal tumor predicted - sensitive IDRX-42 Phase I Actionable In a Phase I trial, IDRX-42 treatment demonstrated safety and resulted in 9 partial responses among 39 evaluable patients with gastrointestinal stromal tumor harboring a KIT exon 11 (n=27), exon 9 (n=13), or exon 8 (n=2) mutation with a clinical benefit rate of 71% overall and 100% as second-line treatment (J Clin Oncol 42, 2024 (suppl 16; abstr 11501); NCT05489237). detail...